Liposomal dry powders as aerosols for pulmonary delivery of proteins

AAPS PharmSciTech

Volumn 6, Issue 4, 2005, Pages

  Lu, Dongmei ^a   Hickey, Anthony J ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Aerosol; Dry powders; Liposome; Lyophilization; Protein; Pulmonary delivery

Indexed keywords

BETA GLUCURONIDASE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; DRUG VEHICLE; MANNITOL;

AEROSOL; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; ENCAPSULATION; FREEZE DRYING; POLYACRYLAMIDE GEL ELECTROPHORESIS; POWDER INHALER; SCANNING ELECTRON MICROSCOPY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INHALATION; AEROSOLS; DRUG DELIVERY SYSTEMS; FREEZE DRYING; LIPOSOMES; POWDERS; PROTEINS;

EID: 30044436097     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt060480     Document Type: Article

References (38)

1. Ahmed T, ed. Clinical testing of aerosol drugs. In: Respiratory Drug Delivery. Boca Raton, FL: CRC Press; 1990:208-242.
2. Schreier H, Gonzales-Rothi RJ, Stecenko, AA. Pulmonary delivery of liposomes. J Control Release. 1993:24:209-223.
3. Zeng XM, Mantin GP, Marriott C. The controlled drug delivery to the lung. Int J Pharm. 1995;124:149-164.
4. Gilbert BE, Wyde PR, Wilson SZ, Robins RK. Aerosol and intraperitoneal administration of ribavarin and ribavarin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/ WDN virus. Antimicrob Agents Chemother. 1991;35:1448-1453.
5. Parthasarathy R, Gilbert B, Mehta K. Aerosol delivery of liposomal all-trans retinoic acid to the lungs. Cancer Chemother Pharmacol. 1999;43:277-283.
6. Suntres ZE, Shek PN. Alleviation of paraquat-induced lung injury by pretreatment with bifunctional liposomes containing α-tocopherol and glutathione. Biochem Pharmacol. 1996;52:1515-1520.
7. Briscoe P, Caniggia I, Graves A, et al. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am J Physiol. 1995;268:L374-L380
8. Thibeault DW, Rezaiekhaligh M, Mabry S, Beringer T. Prevention of chronic pulmonary oxygen toxicity in young rats with liposome-encapsulated catalase administered intratracheally, Pediatr Pulmonol. 1991; 11:318-327.
9. Saari M, Vidgren MT, Kiskinen MO, Turjanmaa VHM, Neiminen MM. Pulmonary distribution and clearance of 2 beclomethasone liposome formulations in healthy volunteers. Int J Pharm. 1999;181:1-9.
10. Lange CF, Hancock REW. Samuel J, Finlay WH, In vitro delivery and regional airway surface liquid concentration of a liposomal cationic peptide. J Pharm Sci. 2001:90:1647-1657.
11. Niven RW, Speer M. Schreier H, Nebulization of liposomes. I, Effects of lipid compositions. Pharm Res. 1992;9:515-520.
12. Hickey AJ, Dunbar CA. A new millennium for inhaler technology. Pharm Technol, 1997;21:116-125.
13. Shreier H, Mobley WC, Concessio N, Hickey AJ, Niven RW, Formulation and in vitro performance of liposome powder aerosols. STP Pharma Sciences. 1994:4:38-44.
14. Lo Y, Tsai J, Kuo J. Liposomes and saccharides as carriers in spray-dried powder formulations of superoxide dismutase. J Control Release. 2004;94:259-272.
15. Joshi MR, Misra A. Liposomal budesonide for dry powder inhaler: preparation and stabilization. AAPS PharmSciTech. 2001;2:E25.
16. Joshi M, Misra A. Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung. Clin Exp Pharmacol Physiol. 2003;30:153-156.
17. Jendle JH, Karlberg B, Arborelius M. An exploration of intrapulmonary insulin administration in anaesthetized and mechanically ventilated pigs. Scand J Clin Lab Invest. 1996;56:251-258.
18. Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptides and proteins: α-interferon, calcitonins, and parathyroid hormone, J Control 1994;28:79-85.
19. Colthorpe P, Farr SJ, Smith IJ, Wyatt D, Taylor G. The influence of regional deposition on the pharmacokinetics of pulmonary-delivered human growth hormone in rabits. Pharm Res. 1995;12:356-359.
20. Lizio R, Klenner T, Borchard G, et al, Systemic delivery of the GnRH antagonist cetrorelix by intratracheal instillation in anesthetized rat. Eur J Pharm Sci. 2000;253-258.
21. Folkesson HG, Westrom BR, Pierzynowski SG, Svendsen J, Karlsson BW. Lung to blood passage of albumin and a nonapeptide after intratracheal instillation in the young developing pig. Acta Physiol Scand. 1993;147:173-178.
22. Russo DM, Kozlova N, Lakey DL, Kernodle D. Na ve human T cells develop into Th1 effectors after stimulation with mycobacterium tuberculosis-infected macrophages or recombinant Ag85 proteins. Infect Immun. 2000;68:6826-6832.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem. 1951;193:265-275.
24. Combie J, Blake JW, Nugent TE, Tobin T. Morphine glucuronide hydrolysis: superiority of beta-glucuronidase from patella vulgata. Clin Chem. 1982;28:83-86.
25. Fisherman WH. Methods for determination of enzyme activity-III Hydrolases: β-Glucuronidase. In: Bergmeywe HU, ed. Method: of Enzymatic Analysis Volume 2, 2nd ed. New York, NY: Academic Press, Inc; 1974:929-943.
26. Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980;104:10-14.
27. Leonard A, Dufourc EJ. Interactions of cholesterol with the membrane lipid matrix: a solid state NMR approach. Biochimie. 1991;73:1295-1302.
28. Colletier, JP. Chaize B, Winterhalter M, Fournier D. Protein encapsulation in liposomes: efficient depends on interaction between protein and phospholipid bilayer. BMC Biotechnol. 2002;2:9-17.
29. Flores H, Ellington AD. Increasing the thermal stability of an oligomeric protein, beta-glucuronidase. J Mol Biol. 2002;315:25-337.
30. Hellman K, Miller DS, Cammack KA. The effects of freeze-drying on the quaternary structure of asparaginase from Erwinia Carotovora. Biochim Biophys Acta. 1983;749:133-142.
31. Clark AR, Egan M. Modeling the deposition of inhaled powdered drug aerosols. J Aerosol Sci 1994;25:175-186.
32. The United States Pharmacopeial Convention The United States Pharmacopoeia and National Formulary. USP24 Rockville, MD: United States Pharmacopoeial Convention; 2000:1895-1912.
33. Hickey AJ, Swift D. Measurements of Pharmaceutical Diagnostic Aerosols. In: Baron PA, Willeke K, eds. Aerosol Measurement: Principles, Techniques and Applications New York: Wiley; 2001:1031-1052.
34. Bell JH, Hartley PS, Cox JSG. Dry powder aerosol. I. A new powder inhalation device. J Pharm Sci. 1971;60:1559-1564.
35. van Winden EC, Zhang W, Crommelin DJ. Effect of freezing rate on the stability of liposomes during freeze-drying and rehydration. Pharm Res. 1997; 14:1151-1160.
36. Hatley RHM, Blair JA. Stabilization and delivery of labile materials by amorphous carbohydrates and their derivatives. J Mol Catal, B Enzym. 1999;7:11-19.
37. Zeng XM, Martin GP, Marriot C. Effects of molecular weight of polyvinylpyrrolidone on the glass transition and crystallization of co-lyophilized sucrose. Int J Pharm. 2001;218:63-73.
38. Shamblin SL, Huang EY, Zografi G. The effects of co-lyophilized polymeric additives on the glass transition temperature and crystallization of amorphous sucrose. J Therm Anal. 1996;47:1567-1579.